DrugPatentWatch Database Preview

Details for Patent: 8,633,309

« Back to Dashboard

Which drugs does patent 8,633,309 protect, and when does it expire?

Patent 8,633,309 protects EPCLUSA, HARVONI, SOVALDI, and VOSEVI, and is included in four NDAs.

This patent has one hundred and seventy patent family members in thirty-seven countries.

Summary for Patent: 8,633,309

Title:	Nucleoside phosphoramidates
Abstract:	Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Inventor(s):	Ross; Bruce (El Granada, CA), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (San Ramon, CA), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (San Jose, CA), Chun; Byoung-Kwon (Robbinsville, NJ), Wang; Peiyuan (Totowa, NJ)
Assignee:	Gilead Pharmasset LLC (Foster City, CA)
Application Number:	13/738,425
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,633,309
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 8,633,309

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-001	Jun 28, 2016		RX	Yes	Yes			Y	Y		FOR THE TREATMENT OF HEPATITIS C
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-001	Oct 10, 2014		RX	Yes	Yes			Y	Y		FOR THE TREATMENT OF HEPATITIS C
Gilead Sciences Inc	SOVALDI	sofosbuvir	TABLET;ORAL	204671-001	Dec 6, 2013		RX	Yes	Yes			Y	Y		FOR THE TREATMENT OF HEPATITIS C
Gilead Sciences Inc	VOSEVI	sofosbuvir; velpatasvir; voxilaprevir	TABLET;ORAL	209195-001	Jul 18, 2017		RX	Yes	Yes			Y	Y		TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
Gilead Sciences Inc	VOSEVI	sofosbuvir; velpatasvir; voxilaprevir	TABLET;ORAL	209195-001	Jul 18, 2017		RX	Yes	Yes			Y	Y		TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR

International Family Members for US Patent 8,633,309

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3515
Argentina	080819
Argentina	080870
Argentina	081813
Argentina	082937
Australia	2010249481
Australia	2011235044